The incidence rate of cases increased 6.7% per year on average between 2011 and 2021, the JAMA-published research revealed.

Advanced prostate cancer cases are rising sharply in California, outpacing national trends, according to a new study from ...

Published in Cell Reports Medicine, results of a VHIO-led study support the feasibility of using RAD51 testing to complement ...

Published in Cell Reports Medicine, results of a VHIO-led study support the feasibility of using RAD51 testing to complement next-generation ...

A new study has identified pathogenic variants in WNT9B as significant risk factors for hereditary prostate cancer. Read more ...

In a video interview, William K. Oh, MD, director of precision medicine at Yale Cancer Center and Smilow Cancer Hospital discusses the latest breakthroughs in advanced prostate cancer treatment.

The methylation of plasma cell-free DNA (cfDNA) has emerged as a valuable diagnostic and prognostic biomarker in various cancers including colorectal cancer (CRC). Currently, there are no biomarkers ...

Prostate cancer (PC) is a prevalent malignancy among males and ranks as the fifth leading cause of cancer-related deaths globally. Factors such as age, ...

The inherited mutated gene WNT9B, which functions normally in embryonic prostate development, increases risk of adult prostate cancer, according to a new study.

(HealthDay News) — For patients with localized prostate cancer (PCa), tissue-based genomic ... Prostate Score (GPS), and Prolaris GCs on risk stratification and patient-clinician decisions ...

A new review led by researchers at Moffitt Cancer Center assessed how three genomic tests — Decipher, Oncotype DX Genomic Prostate Score (GPS) and Prolaris — can help doctors make better decisions ...